Abiomed Second Quarter Fiscal 2020 Earnings and Conference Call Notification
October 10 2019 - 3:55PM
Business Wire
Abiomed, Inc. (NASDAQ: ABMD) announced that on Thursday, October
31, 2019, the Company will release financial results for the second
quarter of fiscal 2020. The Company will host a conference call to
discuss the results on Thursday, October 31, 2019, at 8:00 a.m. ET.
Michael R. Minogue, Chairman, President and Chief Executive Officer
and Todd Trapp, Chief Financial Officer, will host the conference
call.
To listen to the call live, please tune into the webcast via
https://edge.media-server.com/mmc/p/7yfz5bxh or dial (855)
212-2361; the international number is (678) 809-1538. A replay of
this conference call will be available beginning at 11:00 a.m. ET
October 31, 2019 through 10:00 a.m. ET on November 7, 2019. The
replay phone number is (855) 859-2056; the international number is
(404) 537-3406. The replay access code is 7594662.
ABOUT ABIOMED Based in Danvers, Massachusetts, Abiomed,
Inc. is a leading provider of medical devices that provide
circulatory support. Our products are designed to enable the heart
to rest by improving blood flow and/or performing the pumping of
the heart. For additional information, please visit:
www.abiomed.com.
FORWARD-LOOKING STATEMENTS
This release contains forward-looking statements, including
statements regarding development of Abiomed's existing and new
products, the Company's progress toward commercial growth, and
future opportunities and expected regulatory approvals. The
Company's actual results may differ materially from those
anticipated in these forward-looking statements based upon a number
of factors, including uncertainties associated with development,
testing and related regulatory approvals, including the potential
for future losses, complex manufacturing, high quality
requirements, dependence on limited sources of supply, competition,
technological change, government regulation, litigation matters,
future capital needs and uncertainty of additional financing, and
other risks and challenges detailed in the Company's filings with
the Securities and Exchange Commission, including the most recently
filed Annual Report on Form 10-K and Quarterly Report on Form 10-Q.
Readers are cautioned not to place undue reliance on any
forward-looking statements, which speak only as of the date of this
release. The Company undertakes no obligation to publicly release
the results of any revisions to these forward-looking statements
that may be made to reflect events or circumstances that occur
after the date of this release or to reflect the occurrence of
unanticipated events.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20191010005835/en/
Ingrid Goldberg Director, Investor Relations 978-646-1590
igoldberg@abiomed.com
ABIOMED (NASDAQ:ABMD)
Historical Stock Chart
From Mar 2024 to Apr 2024
ABIOMED (NASDAQ:ABMD)
Historical Stock Chart
From Apr 2023 to Apr 2024